Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Abilene, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Abilene, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Arlington, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Beaumont, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Beaumont, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Bedford, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Denton, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Denton, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Flower Mound, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Flower Mound, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Fort Worth, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Garland, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Garland, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
McAllen, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Odessa, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Odessa, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Paris, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Paris, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Round Rock, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Sherman, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Sherman, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Sugar Land, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Temple, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
The Woodlands, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Tyler, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Waco, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Waco, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Webster, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Wichita Falls, TX
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Ogden, UT
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Fairfax, VA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Newport News, VA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Richmond, VA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Winchester, VA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Winchester, VA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Kennewick, WA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Spokane Valley, WA
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
Clinical Research Facility
mi
from
Milwaukee, WI
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated:  2/1/2016
mi
from
Buenos Aires,
A Study in Second Line Metastatic Colorectal Cancer
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Status: Enrolling
Updated: 2/1/2016
mi
from
Buenos Aires,
Click here to add this to my saved trials
Vitamin D and Screening Colonoscopy or Polyp Surveillance
Association of 25-OH Vitamin D Status With Findings on Screening Colonoscopy.
Status: Enrolling
Updated:  2/1/2016
Mike O'Callaghan Federal Hospital/Nellis Air Force Base
mi
from
Las Vegas, NV
Vitamin D and Screening Colonoscopy or Polyp Surveillance
Association of 25-OH Vitamin D Status With Findings on Screening Colonoscopy.
Status: Enrolling
Updated: 2/1/2016
Mike O'Callaghan Federal Hospital/Nellis Air Force Base
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Analyzing the Composition of Tears to Identify Cancer
ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)
Status: Enrolling
Updated:  2/2/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Analyzing the Composition of Tears to Identify Cancer
ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)
Status: Enrolling
Updated: 2/2/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.
Status: Enrolling
Updated:  2/2/2016
Rocky Mountain Cancer Center
mi
from
Denver, CO
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.
Status: Enrolling
Updated: 2/2/2016
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.
Status: Enrolling
Updated:  2/2/2016
Duke Univeristy Medical Center
mi
from
Durham, NC
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.
Status: Enrolling
Updated: 2/2/2016
Duke Univeristy Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Cancer Control Following Polypectomy
Cancer Control Following Polypectomy
Status: Enrolling
Updated:  2/2/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Cancer Control Following Polypectomy
Cancer Control Following Polypectomy
Status: Enrolling
Updated: 2/2/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Community Dissemination of an Evidence-based Colorectal Cancer (CRC) Screening Intervention
Community Dissemination of an Evidence-based CRC Screening Intervention
Status: Enrolling
Updated:  2/2/2016
UCLA Division of Cancer and Prevention Research
mi
from
Los Angeles, CA
Community Dissemination of an Evidence-based Colorectal Cancer (CRC) Screening Intervention
Community Dissemination of an Evidence-based CRC Screening Intervention
Status: Enrolling
Updated: 2/2/2016
UCLA Division of Cancer and Prevention Research
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: Enrolling
Updated:  2/3/2016
Clinical Research Facility
mi
from
Boston, MA
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: Enrolling
Updated: 2/3/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: Enrolling
Updated:  2/3/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: Enrolling
Updated: 2/3/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: Enrolling
Updated:  2/3/2016
Clinical Research Facility
mi
from
San Francisco, CA
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: Enrolling
Updated: 2/3/2016
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: Enrolling
Updated:  2/3/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
Status: Enrolling
Updated: 2/3/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
A 2 Phase Comparison of Pre-operative CT AND PET Images in the Intraoperative Detection of Disease to a Hand-held Probe, and to an Intraoperative CT Scan in Patients Undergoing Surgery for Metastatic Colorectal Cancer.
Status: Enrolling
Updated:  2/3/2016
Ohio State University Medical Center
mi
from
Columbus, OH
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
A 2 Phase Comparison of Pre-operative CT AND PET Images in the Intraoperative Detection of Disease to a Hand-held Probe, and to an Intraoperative CT Scan in Patients Undergoing Surgery for Metastatic Colorectal Cancer.
Status: Enrolling
Updated: 2/3/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
St. Josephs/Cander Hospital
mi
from
Savannah, GA
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
St. Josephs/Cander Hospital
mi
from
Savannah, GA
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
Kaiser Permanente
mi
from
Hilo, HI
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
Kaiser Permanente
mi
from
Hilo, HI
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
Ingalls Memorial Hospital
mi
from
Harvey, IL
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
Kansas City Cancer Center
mi
from
Kansas City, MO
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
Kansas City Cancer Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
Texas A & M university / Scott and White Clinic
mi
from
Temple, TX
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
Texas A & M university / Scott and White Clinic
mi
from
Temple, TX
Click here to add this to my saved trials